• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen, Boston Children’s Hospital partner to find genes linked to pain disorders

October 17, 2017 By Sarah Faulkner

AmgenAmgen (NSDQ:AMGN) announced today that it inked a one-year collaboration with Boston Children’s Hospital to study patients with pain syndromes in an effort to identify potential genetic targets.

The collaboration will combine Amgen’s work in genetic target identification and the division of pain medicine at Boston Children’s Hospital.

“Traditional approaches to analgesic drug discovery have been pretty disappointing during the past 20 years,” Dr. Charles Berde, chief of the division of pain medicine at Boston Children’s Hospital, said in prepared remarks.

“The most innovative biotech companies have realized that they need to pursue new directions for drug discovery. Patients with unusual patterns of increased or decreased pain responsiveness can offer important clues in this pursuit.”

The group is slated to study patients with erythromelalgia, paroxysmal extreme pain disorder, hereditary sensory and autonomic neuropathy, and with genetic disorders that diminish sensitivity to pain.

“Amgen is pleased to enter into this collaboration as it underscores our extensive investment and expertise in pursuing targets that have clear genetic support,” John Dunlop, Amgen’s VP of neuroscience research, added. “We look forward to working with Boston Children’s Hospital to explore novel pain targets that will potentially include new non-addictive approaches to treating pain in patients.”

Filed Under: Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, Boston Children's Hospital

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS